The Comparative Effects of Valsartan and Amlodipine on vWf Levels and N L Ratio in Patients with Newly Diagnosed Hypertension

High levels of circulating Von Willebrand factor (vWf) and increased neutrophil to lymphocyte (N/L) ratio may reflect vascular inflammation in hypertensive patients. In present study, we aimed to investigate the effects of valsartan as an angiotensin II receptor antagonist and amlodipine as a calciu...

Full description

Saved in:
Bibliographic Details
Published in:Clinical and experimental hypertension (1993) 2013-01, Vol.35 (7), p.516-522
Main Authors: Karaman, Murat, Balta, Sevket, AY, Seyit Ahmet, Cakar, Mustafa, Naharci, Ilkin, Demirkol, Sait, Celik, Turgay, Arslan, Zekeriya, Kurt, Omer, Kocak, Necmettin, Sarlak, Hakan, Demirbas, Seref, Bulucu, Fatih, Bozoglu, Ergun
Format: Article
Language:English
Subjects:
Adult
amlodipine
Amlodipine - therapeutic use
Angiotensin II Type 1 Receptor Blockers - therapeutic use
Antihypertensive Agents - therapeutic use
Biomarkers - blood
Blood Pressure - drug effects
Calcium Channel Blockers - therapeutic use
Essential Hypertension
Female
Humans
Hypertension - blood
Hypertension - drug therapy
Hypertension - physiopathology
Leukocyte Count
Lymphocytes - pathology
Male
Middle Aged
N/L ratio
Neutrophils - pathology
newly diagnosed hypertension
Prospective Studies
Tetrazoles - therapeutic use
Valine - analogs & derivatives
Valine - therapeutic use
Valsartan
von Willebrand Factor - metabolism
vWf levels
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:High levels of circulating Von Willebrand factor (vWf) and increased neutrophil to lymphocyte (N/L) ratio may reflect vascular inflammation in hypertensive patients. In present study, we aimed to investigate the effects of valsartan as an angiotensin II receptor antagonist and amlodipine as a calcium channel blocker on the vWf levels and N/L ratio in patients with essential hypertension. Patients were randomized to one of the following intervention protocols: calcium channel blocker (amlodipine, 5-10 mg/day) as group A (n = 20 mean age = 51.85 ± 11.32 y) and angiotensine II receptor blocker (valsartan, 80-320 mg/day) as group B (n = 26 mean age = 49.12 ± 14.12 y). Endothelial dysfunction and vascular inflammation were evaluated with vWf levels and N/L ratio in hypertensive patients before treatment and after treatment in the 12th week. No statistically significant differences were found among the groups in terms of age, sex, and body mass index (BMI). There was a significant decrease in vWf levels (P < .001) and N/L ratio after treatment (P = .04, P < .001, respectively) in both the groups. Von Willebrand factor levels and N/L ratio are very important markers having a role in vascular inflammation and antihypertensive treatment with amlodipine and valsartan may improve cardiovascular outcomes by decreasing these biomarkers.
ISSN:1064-1963
1525-6006
DOI:10.3109/10641963.2012.758734